Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Total Liabilities (2020 - 2025)

PROCEPT BioRobotics has reported Total Liabilities over the past 6 years, most recently at $142.2 million for Q4 2025.

  • Quarterly results put Total Liabilities at $142.2 million for Q4 2025, up 7.9% from a year ago — trailing twelve months through Dec 2025 was $142.2 million (up 7.9% YoY), and the annual figure for FY2025 was $142.2 million, up 7.9%.
  • Total Liabilities for Q4 2025 was $142.2 million at PROCEPT BioRobotics, up from $131.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for PRCT hit a ceiling of $206.3 million in Q2 2021 and a floor of $68.2 million in Q3 2021.
  • Median Total Liabilities over the past 5 years was $122.2 million (2023), compared with a mean of $120.2 million.
  • Biggest five-year swings in Total Liabilities: tumbled 65.23% in 2022 and later soared 63.33% in 2023.
  • PROCEPT BioRobotics' Total Liabilities stood at $69.9 million in 2021, then soared by 60.52% to $112.3 million in 2022, then increased by 10.43% to $124.0 million in 2023, then rose by 6.32% to $131.8 million in 2024, then rose by 7.9% to $142.2 million in 2025.
  • The last three reported values for Total Liabilities were $142.2 million (Q4 2025), $131.3 million (Q3 2025), and $127.3 million (Q2 2025) per Business Quant data.